Evaluation of the Association Between DNA Methylation and Shortened Survival in Patients With Advanced Colorectal Cancer Treated With 5-FU/Oxaliplatin-Based Regimens in E3200
Evaluation of the Association Between DNA Methylation and Shortened Survival in Patients With Advanced Colorectal Cancer Treated With 5-FU/Oxaliplatin-Based Regimens in E3200
RATIONALE: Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.
PURPOSE: This laboratory study is analyzing the DNA in tissue samples from patients with advanced colorectal cancer treated with fluorouracil and oxaliplatin with or without bevacizumab on clinical trial E-3200.
OBJECTIVES:
OUTLINE: This is a multicenter study.
Tissue, blood, and urine samples and genomic DNA samples from tumor tissue blocks are examined by pyrosequencing assay for methylation. Genes examined include MINT1, MINT31, P14, and P16. Microsatellite instability and loss of heterozygosity (LOH) on chromosome 18 (18q LOH) are also assessed. Microsatellites examined include BAT loci, TGFβRII, D2S123, D55346, and D17S250.
PROJECTED ACCRUAL: A total of 350 specimens will be accrued for this study.
DISEASE CHARACTERISTICS:
Diagnosis of adenocarcinoma of the colon or rectum
Enrolled on clinical trial E-3200 and received fluorouracil and oxaliplatin
Tumor tissue blocks available
Routine pathology specimens (i.e., blood, urine) available
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY: